-
Premature Ischemia
-
Beta-Blockers May Be Useful for Noncardiac Surgery; Promising New Weight Loss Drug?; Treating Shift-Work Disorder; Another Flu Vaccine Shortage?; FDA Actions
-
Symptoms of lower extremity venous disease are directly related to the degrees of visible and functional disease, but may occur even in legs that appear normal.
-
Two recent studies shed further light on the short-term use of parathyroid hormone (PTH) to enhance the treatment of osteoporosis. PTH is approved for use up to 2 years in patients with moderate-to-severe osteoporosis. The anabolic bone formation induced by PTH is largely lost after stopping therapy, but is well maintained by continued therapy with a biphosphonate. PTH may be given continuously or cyclically to enhance bone formation.
-
Women with polycystic ovaries demonstrate a definite rate of worsening glucose tolerance and conversion to type 2 diabetes mellitus.
-
The FDA has approved tigecycline, the first of a new class of antimicrobial agents. The drug is a novel parenteral antibiotic that is chemically similar to minocycline. It is active against a wide variety of bacteria that cause complicated intra-abdominal and complicated skin and skin structure infections including methicillin-resistant Staphylococcus aureus (MRSA). Tigecycline is marketed by Wyeth as Tygacil.
-
-
The Use of Prophylactic Antibiotics for Neutropenia; Is It Hot In Here?; Homeopathy vs Conventional Medicine; FDA Actions
-
The decline in VO2 in healthy adults is not constant across age spans but accelerates markedly with each successive age decade despite increases in leisure time physical activity. The decline in aerobic capacity is greater in men than women.
-
The FDA has approved the first melatonin receptor agonist for the treatment of insomnia. Ramelteon differs from benzodiazepine and nonbenzo-diazepine sedative hypnotics in that it is a non-scheduled drug and it is approved for long term use. It is marketed by Takeda Pharmaceutical America, Inc as Rozerem.
